Review Article
An Update on Clinicopathological and Molecular Features of Plexiform Fibromyxoma
Table 3
Pathological and immunohistochemical profiles of PF cases reported in the literature.
| No | Year | Author | Age | Sex | Ki-67 | Vim | SMA | MSA | DOG-1 | CD117 | CD34 | Desmin | Cald | S-100 protein | Calp | EMA | NF | CK | ER | PR | CD10 | β-C | ALK | AE1/AE3 | SNP | C-KIT | PDFGRA |
| 1 | 2007 | Takahashi | 50 | M | <1% | + | + | + | | - | - | - | +/- | - | | | - | - | | | | - | | | | - | - |
| 2 | 2007 | Takahashi | 68 | M | <1% | + | + | + | | - | - | - | +/- | - | | | - | - | | | | - | | | | - | - |
| 3 | 2008 | Galant | 61 | M | | + | + | | | - | - | - | | - | | - | | | | | | | | | | | |
| 4 | 2008 | Rau | 50 | F | 2% | | + | + | | - | +/- (focal) | +/- (sporadic) | | - | | | | | | | | - | - | | | - | - |
| 5 | 2008 | Yoshida | 19 | F | | | | | | - | - | | | - | | - | | | - | - | - | | | | | - | - |
| 6 | 2008 | Yoshida | 46 | M | <1% | | + | + | | - | - | +/- (focal) | + (partial) | - | + (partial) | | | | | | | | | - | | - | - |
| 7 | 2009 | Miettinen | 38 | F | | | + (8/10) | | - | - | - | - | - (3/3) | - | | | | | | | + (1/3), -(2/3) | | | - (3/3) | | wt (3/3) | wt (3/3) | 8 | 2009 | Miettinen | 62 | M | | | | - | - | - | - | - | | | | | | | | | | 9 | 2009 | Miettinen | 75 | F | | | | - | - | - | - | - | | | | | | | | | | 10 | 2009 | Miettinen | 65 | F | | | | - | - | - | - | - | | | | | | | | | | 11 | 2009 | Miettinen | 33 | M | | | | - | - | - | - | - | | | | | | | | | | 12 | 2009 | Miettinen | 43 | M | | | | - | - | - | - | - | | | | | | | | | | 13 | 2009 | Miettinen | 56 | F | | | | - | - | - | - | - | | | | | | | | | | 14 | 2009 | Miettinen | 50 | M | | | | - | - | - | - | - | | | | | | | | | | 15 | 2009 | Miettinen | 21 | M | | | | - | - | - | - | - | | | | | | | | | | 16 | 2009 | Miettinen | 16 | F | | | | - | - | - | - | - | | | | | | | | | | 17 | 2009 | Miettinen | 30 | F | | | | - | - | - | - | - | | | | | | | | | | 18 | 2009 | Miettinen | 7 | F | | | | - | - | - | - | - | | | | | | | | | |
| 19 | 2009 | Pailoor | 23 | F | | + | + | | | - | - | +/- (partial) | | - | | | | | | | | | | | | | |
| 20 | 2010 | Sing | 35 | F | + | | + | + | | - | - | + | + | - | + | | | | - | + | - | - | - | - | | | |
| 21 | 2010 | Takahashi | 23 | M | | + | | + | | - | - | | | - | | - | - | - | | | | | - | | | - | - |
| 22 | 2010 | Tan | 34 | M | <2% | | + | | | - | - | + | | - | | | | | | | | | | | | - | - |
| 23 | 2010 | Wang | 54 | F | <1% | + | + | | | - | - | | | - | | | | | | | | | | | | | |
| 24 | 2010 | Cooper | 64 | M | | | + | + | - | - | - | | | - | | - | | | | | | - | | | | | |
| 25 | 2011 | Kim | 52 | M | | | + | | | - | | +/- (partial) | | - | | | | | | | | | | | | | |
| 26 | 2012 | Kang | 47 | M | 6% | | + | | | - | - | - | | - | | - | - | | | | | | | | | | |
| 27 | 2012 | Kang | 63 | F | | | + | | | - | - | - | | - | | - | | | | | | | | | | wt | wt |
| 28 | 2012 | Schulz | 59 | M | <2% | | + | | | - | - | - | | - | | - | - | | | | | | - | - | | | |
| 29 | 2012 | Cai | 32 | M | | | + | + | | - | - | | | - | | | | | | | | | | | | | |
| 30 | 2012 | Cai | 47 | F | | | + | + | | - | - | | | - | | | | | | | | | | | | | |
| 31 | 2012 | Wang | 12 | M | | | + | + | - | - | - | | | - | | | | | | | | | | | | | |
| 32 | 2012 | Miettinen | 49 | F | | + | + | | | - | | | | | | | | | | | + (variably) | | | | | | |
| 33 | 2012 | Li | 47 | F | <1% | | + | | | - | - | | - | - | | | | | | | | - | - | | | | |
| 34 | 2012 | Bi | 31 | M | | | + | + | | | | | | | | + | | | | | | | | | | | |
| 35 | 2012 | Bi | 47 | F | | | + | + | | | | | | | | | | | | | | | | | | | |
| 36 | 2012 | Bi | 42 | F | | | + | + | | | | + | + | | | | | | | + | + | | | | | | |
| 37 | 2014 | Baek | 38 | F | | | + | | | - | - | | | - | | | | | | | | | | | | | |
| 38 | 2014 | Duckworth | 16 | F | 1% (focally 8%) | | + | | - | - | - | - | | - | | | | | | | | | | | | | |
| 39 | 2014 | Duckworth | 11 | F | | + | + | | | - | - | + | | - | + | | | | | | | | - | - | - | | |
| 40 | 2014 | Ikemura | 27 | F | Small Percentage | | + | | | - | - | +/- (partial) | | | | | | | - | - | + | | | | | | |
| 41 | 2014 | Lee | 42 | F | | | + | + | - | - | - | - | | - | | | | | | | | - | | | | | |
| 42 | 2014 | Li | 32 | M | <1% | + | +/- (partial) | | - | - | - | + (partial) | + (partial) | - | | | | | | | | - | - | | | | |
| 43 | 2014 | Sakamoto | 60 | M | | | - | | - | - | - | | | - | | | | | | | - | | | | | | |
| 44 | 2014 | Li | 73 | F | | + | + | | | - | - | | | - | | | | | | | | | | | | | |
| 45 | 2014 | Tian | 64 | M | | | + | | - | - | - | | | | | | | | | | | | | | | | |
| 46 | 2015 | Banerjee | 19 | F | | | - | - | - | - | - | - | | - | - | | | | | | - | | | | | | |
| 47 | 2015 | Fassan | 55 | F | 0% | + | + | + | | - | + | - | | - | | - | | | | | - | | | | | - | - |
| 48 | 2015 | Lu | 26 | F | | + | + | | - | - | - | | | | | | | | | | | | | | | | |
| 49 | 2015 | Ni | 21 | F | 5% | + | + | | - | - | - | | | - | | - | | | | | | | | | | | |
| 50 | 2015 | Wei | 50 | F | | | + | | - | | | | | - | | | | | | | | | | | | | |
| 51 | 2015 | Yue | 34 | M | | | + | + | - | - | - | | | - | | | | | | | | | | | | | |
| 52 | 2015 | Yue | 50 | F | | | + | + | - | - | - | | | - | | | | | | | | | | | | | |
| 53 | 2015 | Xu | 50 | F | <1% | + | + | | - | - | - | | | - | | | | | | | | | | | - | | |
| 54 | 2016 | Dixit | 51 | F | <1% | | + | | | - | - | | - | - | | | | | | | | - | - | | | | |
| 55 | 2016 | Inoue | 36 | F | | | | | | | | | | | | | | | | | | | | | | | |
| 56 | 2016 | Jonaitis | 28 | F | 40% (vascular endothelial Ki-67) | | + | | | | - | - | | - | | | | | | | | | | | | | |
| 57 | 2016 | Kane | 28 | F | | | + | | - | - | - | | | - | | | | | | | +/- (focal) | - | | - | | | |
| 58 | 2016 | Morris | 9 | F | | | + | | - | - | - | +/- (focal) | | - | + | | | - | | | +/- (focal) | | - | | | | |
| 59 | 2016 | Nagahisa | 39 | M | | | + | | | - | - | | | - | | | | | | | | | | | | | |
| 60 | 2016 | Quero | 47 | M | | + | + | | - | - | - | +/- (partial) | +/- (partial) | - | | - | | | | | +/- (partial) | | - | +/- (focal) | - | wt | wt |
| 61 | 2016 | Spans | 19 | M | | | + | | | - | - | - | | - | | | | | | | | | - | | | | |
| 62 | 2016 | Spans | 65 | F | | | + | | | - | - | - | | - | | - | | | | | | | - | | | | |
| 63 | 2016 | Spans | 58 | F | | | + | | | - | - | - | | - | | - | | | | | | | - | | | | |
| 64 | 2016 | Spans | 51 | F | | | + | | | | | +/- (focal) | | - | | | | | | | | | | | | | |
| 65 | 2016 | Spans | 63 | F | | | + | | | | | +/- (focal) | | - | | | | | | | | | | | | | |
| 66 | 2016 | Spans | 76 | F | | | +/- (focal) | | | | | + | | | | | | | | | | | | | | | |
| 67 | 2016 | Spans | 62 | F | | | | | | | | +/- (focal) | | - | | | | | | | | | | | | | |
| 68 | 2016 | Spans | 30 | F | | | + | | | | | + | | | | | | | | | | | | | | | |
| 69 | 2016 | Spans | 28 | M | | | + | | | | - | +/- (focal) | | + | | | | | | | | | - | | | | |
| 70 | 2016 | Spans | 44 | F | | | | | | | +/- (focal) | + | | - | | | | | | | | | | | | | |
| 71 | 2016 | Spans | 18 | F | | | +/- (focal) | | | | | +/- (focal) | | | | | | | | | | | | | | | |
| 72 | 2016 | Spans | 19 | F | | | + | | | - | - | - | | - | | - | | | | | | | | | | | |
| 73 | 2016 | Spans | 46 | M | | | + | | | | - | - | | - | | | | | | | | | | | | | |
| 74 | 2016 | Spans | 29 | M | | | + | | | - | - | - | | - | | | | | | | | | - | | | | |
| 75 | 2016 | Spans | 36 | F | | | + | | | - | - | - | | - | | | | | | | | | | | | | |
| 76 | 2016 | Spans | 47 | F | | | + | | | - | - | - | | - | | | | | | | | | | | | | |
| 77 | 2016 | Li | 11 | M | | | + | | | - | - | | + | | | | | | | | | | | | | | |
| 78 | 2016 | Zhang | 48 | M | | + | + | | - | - | - | | | - | | | | | | | | | | | | | |
| 79 | 2016 | Li | 44 | F | | + | - | | | - | + | - | | - | | | | | | | | | | | | | |
| 80 | 2017 | Akai | 55 | M | | + | - | | | - | + | - | | - | | | | | |
| | | | | | | |
| 81 | 2017 | Gonzalez-Cordero | 37 | M | | | | + | - | - | - | + | | - | | | | | | | + | | - | | | | |
| 82 | 2017 | Hu | 26 | M | | + | + | | - | - | +/- (negative/focal) | +/- (patchy, 5/10) | +/- (patchy, 6/10) | - | | | | | - | + (patchy/ diffusely at nucleus, 6/10) | + (patchy, 5/10) | | - | | | wt (5/10) | wt (5/10) | 83 | 2017 | Hu | 31 | F | | + | + | | - | - | - | | | | | - | | - | | | 84 | 2017 | Hu | 72 | F | | + | + | | - | - | - | | | | | - | | - | | | 85 | 2017 | Hu | 59 | F | | + | + | | - | - | - | | | | | - | | - | | | 86 | 2017 | Hu | 52 | M | | + | + | | - | - | - | | | | | - | | - | | | 87 | 2017 | Hu | 59 | F | | + | + | | - | - | - | | | | | - | | - | | | 88 | 2017 | Hu | 48 | M | | + | + | | - | - | - | | | | | - | | - | | | 89 | 2017 | Hu | 58 | M | | + | + | | - | - | - | | | | | - | | - | | | 90 | 2017 | Hu | 46 | M | | + | + | | - | - | - | | | | | - | | - | | | 91 | 2017 | Hu | 40 | F | | + | + | | - | - | - | | | | | - | | - | | |
| 92 | 2017 | Kawara | 66 | M | 2% | | + (focal) | + (focal) | - | - | - | - | - | - | + (focal) | | | | | | - | | | | | | |
| 93 | 2017 | Kim | 51 | M | | | + | | | - | | | | | | | | | | | | | | | | | |
| 94 | 2017 | Liang | 11 | M | | | + (focal) | | - | - | - | - | + (focal) | - | + (focal) | | | | | | | | - | | | | |
| 95 | 2017 | Moris | 63 | M | | | + | | - | - | - | - | | - | | | | | | | | | | | | wt | wt |
| 96 | 2017 | Qi | 42 | M | 1% | + | + | | - | - | - | + (partial) | + (partial) | - | + (partial) | - | | | | | - | | | - | | | |
| 97 | 2017 | Qi | 66 | M | 1% | + | + | | - | - | - | | | - | | - | | | | | - | | | - | | | |
| 98 | 2017 | Szurian | 16 | F | | | + | | - | - | - | + (focal) | + (focal) | - | | | | | | | +/- (focal) | - | - | | | - | - |
| 99 | 2017 | Szurian | 34 | M | | | + | | - | - | - | - | - | - | | | | | | | +/- (focal) | - | - | | | | |
| 100 | 2017 | Wambura | 41 | F | | | + | | - | - | | - | | - | | | | | | | - | | | | | | |
| 101 | 2017 | Yang | 50 | F | 3% | + | + | | - | - | + | - | | - | | - | | - | | | - | - | - | | | | |
| 102 | 2017 | Zhou | 51 | M | 1% | | + | | - | - | - | - | | - | | | | | | | | | | - | | - | - |
| 103 | 2018 | Djurić | 14 | M | | | + | | - | - | - | + (focal) | | - | | | - | | | | | | - | | | | |
| 104 | 2018 | Jang | 47 | F | | | + | | - | - | - | + (focal) | | - | | - | | | | | + (focal) | | | | | | |
| 105 | 2018 | Rohit | 81 | F | | | + (patchy) | | - | - | - | - | | - | | | | | | | | | | - | | | |
| 106 | 2018 | Wang | 52 | F | 1% | | + | | - | - | - | - | | + | | - | | | | | + | | | | | | |
| 107 | 2018 | Zhang | 31 | F | <5% | | + | | - | - | - | - | | - | | - | | - | | | + (partial) | | | | | | |
| 108 | 2019 | Wu | 59 | F | | | + | | - | - | - | +/- (focal) | | - | | - | | | | | | - | - | | | | |
| 109 | 2019 | Fukazawa | 14 | F | 2% | + | + | | - | - | - | - | | - | | | | | | | | | - | | | | |
| 110 | 2019 | Banerjee | 65 | M | | | + | | - | - | - | | | - | | | | | | | | | | | | | |
| 111 | 2019 | Lai | 21 | F | | | + | | | - | - | - | | - | | | | | | | | | | | | | |
| 112 | 2019 | Lai | 42 | F | | | | | - | - | - | - | | - | | | | | | | | | | | | | |
| 113 | 2019 | Lai | 79 | F | 30% | | + | | - | - | - | +/- (focal) | | - | | | | | | | | | | | | | |
| 114 | 2019 | Lai | 33 | M | | | + | | | - | - | +/- (focal) | | - | | | | | | | | | | | | | |
| 115 | 2019 | Lai | 60 | M | | | + | | - | - | - | + (focal) | | - | | | | | | | | | | | | | |
| 116 | 2019 | Lai | 77 | M | | | + | | - | - | - | | | | | | | | | | | | | | | | |
| 117 | 2019 | Lai | 45 | M | | | + | | - | - | - | | | | | | | | | | | | | | | | |
| 118 | 2019 | Li | 5 | M | | + | + | | - | - | - | - | | - | | | | | | | | - | | | | | |
|
|
Abbreviations: Dx, diagnosis; Vim, vimentin; Cald, caldesmon; Calp, calponin; NF, neurofilament; CK, cytokeratin; β-C, β-catenin; SNP, synaptophysin; wt, wild type. |